三鑫医疗: 关于2024年限制性股票激励计划第一个解除限售期解除限售条件成就的公告

Core Viewpoint - The announcement details the achievement of the first unlock period conditions for the 2024 restricted stock incentive plan, allowing 112 eligible participants to unlock a total of 3.849575 million shares, representing 0.7369% of the company's total share capital [1][12]. Summary by Sections Incentive Plan Overview - The 2024 restricted stock incentive plan was approved in meetings held on July 29 and August 14, 2024, with a total of 116 participants receiving 8.13565 million shares after adjustments [2][6]. - The plan's duration is up to 48 months from the date of stock grant registration [2]. Unlock Conditions - The first unlock period allows for 50% of the granted shares to be unlocked after 12 months, and the remaining 50% after 24 months [2]. - The performance assessment for the unlock conditions is based on the company's financial performance in 2024 and 2025, with specific revenue and profit growth targets set [2][4]. Performance Targets - For the first unlock period, the company must achieve either a 15% revenue growth or a 10% net profit growth compared to 2023 [3][4]. - For the second unlock period, the targets include a 26.5% revenue growth or a 15% net profit growth over the two-year period [4]. Performance Assessment Results - The company reported a revenue of 1,500.4384 million yuan for 2024, achieving a 15.41% growth, and a net profit of 209.8692 million yuan, achieving a 15.35% growth [15]. - The personal performance assessment for the participants resulted in a 100% unlock ratio for 29 individuals, while 12.325 million shares were subject to repurchase due to unmet conditions [16][17]. Approval and Legal Compliance - The board and supervisory committee confirmed that all necessary approvals and legal requirements were met for the unlock conditions to be fulfilled [19][20]. - The legal opinion from Jiangxi Huabang Law Firm affirmed the legitimacy of the unlock conditions and the eligibility of the participants [19][20].